COVID update 2024:
In difficult times for humanity we find application of our patented nanotechnologies in the diagnosis and therapy of Covid-19.
In difficult times for humanity we find application of our patented nanotechnologies in the diagnosis and therapy of Covid-19.
Newly synthesized chloroquine and hydroxychloroquine analogues loaded in I-CAN™.
We focus our efforts on solving the problem with drug delivery. Novel isoquinolines and derivative condensed structures, synthesized to inhibit SARS-CoV to enter the cell, are incorporated into unique biodegradable and biodigestible solid lipid nanoparticles using I-CAN™ technology. This would dramatically affect the interaction of these drugs with the target receptors- we reach highest level of efficacy with up to 80 times reduced doses.
Rapid diagnosis and monitoring of Coronaviruses: Fluorescent RNA dyes encapsulated in I-CAN™ nanoparticles.
We integrated CellInject™ technology to deliver the diagnostic agents through “in-cell-only” mechanism.
I-CAN™ nanocarrier is capable to encapsulate active substances with low bioavailability and to transport them unchanged through cell membranes- the weak nuclear membrane permeability of the RNA dyes is not a problem anymore.
I-CAN™ nanocarrier is capable to encapsulate active substances with low bioavailability and to transport them unchanged through cell membranes- the weak nuclear membrane permeability of the RNA dyes is not a problem anymore.
Additive antiviral effect: I-CAN™ nanoparticles as delivery systems for Ribavirin derivatives.
We investigate the anti-coronaviral activity of newly synthesized derivatives of Ribavirin,
loaded in I-CAN™. Due to its high affinity to lipid membranes and its nano-dimension, the particle flawlessly enters the cell, where the active substance is released. This delivery secures high concentration of antiviral agent within the target cells, and null extracellular release.
loaded in I-CAN™. Due to its high affinity to lipid membranes and its nano-dimension, the particle flawlessly enters the cell, where the active substance is released. This delivery secures high concentration of antiviral agent within the target cells, and null extracellular release.
Overview
“The tremendous scientific progress raised medicine to new levels of knowledge about diagnosis, treatment and prophylaxis of diseases, important to the society. New demands for safety, efficacy and quality are targeted in the pursuit of higher quality of life.
Lead Biotherapeutics has the response:
“Less is more”. We developed highly focused intracell drug delivery technologies allowing 20 to 80 and more times reduction of the usual doses of known therapies. We believe that our inventions will help millions of people, including our children, our parents and ourselves.”
Christo Tzachev, PhD,
Founder and CEO
Lead Biotherapeutics Ltd.
Lead Biotherapeutics has the response:
“Less is more”. We developed highly focused intracell drug delivery technologies allowing 20 to 80 and more times reduction of the usual doses of known therapies. We believe that our inventions will help millions of people, including our children, our parents and ourselves.”
Christo Tzachev, PhD,
Founder and CEO
Lead Biotherapeutics Ltd.
LESS IS MORE concept. Clinically Proven.
Up to 20 X reduction in the single dose of known therapies
Up to 80 X reduction in the daily dose of known therapies
Controllable duration
(depo-effect) up to 10 days
Lead Biotherapeutics LTD has developed innovative proprietary drug delivery platform providing outstanding therapeutic opportunities:
• Up to 20 times reduction in the usual therapeutic dose.
• Up to 4 times reduction in the number of daily dose (i.e. up to 80 times reduction in the total daily intake).
• Controllable depo-effect lasting between 24h and 10 days.
• Up to 20 times reduction in the usual therapeutic dose.
• Up to 4 times reduction in the number of daily dose (i.e. up to 80 times reduction in the total daily intake).
• Controllable depo-effect lasting between 24h and 10 days.
Our fundamental technology
Lead Biotherapeutics LTD has developed Revolutionary Solid Lipid Nanoparticle (SLN) system trademarked as CellInject™ Technology for intracellular release of active substances, with highest safety and efficacy with applications in medicine and cosmetics.
CellInject™ is biocompatible biodegradable and safe SLN system with unique composition and mechanism of intracell targeted delivery.
CellInject™ is biocompatible biodegradable and safe SLN system with unique composition and mechanism of intracell targeted delivery.
Our applied technology
I-CAN™ Technology is a unique combination of Cellinject™ Technology with mucoadhesive carrier giving the system prolonged contact when applied to mucus membranes. While Cellinject™ is non-adhesive to body proteins and glycoproteins due to its highly lipophilic structure and it freely travels through the body liquids, the adhesiveness of I-CAN™ guarantees the time for contact needed for complete CellInject™ absorption.
We Identify modern therapy problems
Today many therapies including the treatment of social diseases like diabetes, Parkinson’s, Alzheimer’s, cancer, chronic inflammation etc., are affected by obstacles originating from the used drug itself and the limitations of pharmaceutical forms:
• Low systemic or local bioavailability of the applied drug (e.g. insolubility, ionization, substrate of p-Glycoprotein efflux pump, extensive pre-systemic metabolism, chemical instability).
• Small therapeutic window.
• Fast elimination.
• Low systemic or local bioavailability of the applied drug (e.g. insolubility, ionization, substrate of p-Glycoprotein efflux pump, extensive pre-systemic metabolism, chemical instability).
• Small therapeutic window.
• Fast elimination.
Our Solution:
Targeting the majority of existing and future drugs into cells can lead to a significant (sometimes dramatic) increase in drug action and safety.
Targeting the majority of existing and future drugs into cells can lead to a significant (sometimes dramatic) increase in drug action and safety.
For more details or questions regarding any aspect of our R&D write us using the Contact page.